Diagnostic delay and morbidity of central nervous system tumors in children and young adults: a pediatric hospital experience
For children with central nervous system (CNS) tumors, survival rates remain significantly lower than other childhood malignancies with a substantial increase in disability of survivors. Given this, it is imperative that these children are identified at the earliest sign of symptom onset. Our institution aimed to identify diagnostic delays, morbidity and mortality, and specific barriers that may exist within our specific healthcare system that result in diagnostic delay.
A retrospective chart review was performed of newly diagnosed CNS tumors between January 1, 2008 and December 31, 2017.
235 patient cases were reviewed, 34 (14.5%) of which had an associated tumor predisposition syndrome. Median age at the time of diagnosis was 9 years (range 1 day to 25 years), with median number of days from symptom onset to definitive diagnosis of 42 days (interquartile range 14–120 days). Delays longer than 60 days occurred in 95 (47.5%) patients. The 10 year relative survival rate for all tumors was 86.8%.
Our institution had a shorter interval from symptom onset to diagnosis than currently reported in the literature, as well as a decrease in associated morbidity. In addition, for those with longer delays, we were able to characterize the etiology and barriers leading to these delays. With these identified, we are able to utilize this knowledge to further improve education and awareness in community members and healthcare professionals to continue to improve the time to diagnosis in the future.
KeywordsChildhood Pediatric Brain Tumor Delayed Diagnosis
Compliance with ethical standards
Conflicts of interest
All authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study conducted, formal consent is not required.
For this type of study conducted, formal consent is not required.
- 3.Curtin SC, Minino AM, Anderson RN (2016) Declines in cancer death rates among children and adolescents in the United States, 1999–2014. NCHS Data Brief 257:1–8Google Scholar
- 8.Aware HBBT (2016) A new clinical guideline from the Royal College of Paediatrics and Child Health with a national awareness campaign accelerates brain tumor diagnosis in UK children—”HeadSmart: be brain tumour aware”. Neuro Oncol 18:445–454. https://doi.org/10.1093/neuonc/nov187 CrossRefGoogle Scholar
- 9.Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, Campbell C, Andersen RS, Hamilton W, Olesen F, Rose P, Nafees S, van Rijswijk E, Hiom S, Muth C, Beyer M, Neal RD (2012) The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer 106:1262–1267. https://doi.org/10.1038/bjc.2012.68 CrossRefGoogle Scholar
- 11.Northrup H, Krueger DA, Group ITSCC (2013) Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49:243–254. https://doi.org/10.1016/j.pediatrneurol.2013.08.001 CrossRefGoogle Scholar
- 12.Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, Nathanson KL, States LJ, Tomlinson GE, Villani A, Voss SD, Schiffman JD, Wasserman JD (2017) Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23:e68–e75. https://doi.org/10.1158/1078-0432.CCR-17-0547 CrossRefGoogle Scholar
- 13.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1 CrossRefGoogle Scholar
- 21.Azizi AA, Heßler K, Leiss U, Grylli C, Chocholous M, Peyrl A, Gojo J, Slavc I (2017) From symptom to diagnosis-the prediagnostic symptomatic interval of pediatric central nervous system tumors in Austria. Pediatr Neurol 76:27–36. https://doi.org/10.1016/j.pediatrneurol.2017.08.006 CrossRefGoogle Scholar
- 22.Fukuoka K, Yanagisawa T, Suzuki T, Shirahata M, Adachi JI, Mishima K, Fujimaki T, Matsutani M, Nishikawa R (2014) Duration between onset and diagnosis in central nervous system tumors: impact on prognosis and functional outcome. Pediatr Int 56:829–833. https://doi.org/10.1111/ped.12369 CrossRefGoogle Scholar
- 24.Flores LE, Williams DL, Bell BA, O’Brien M, Ragab AH (1986) Delay in the diagnosis of pediatric brain tumors. Am J Dis Child 140:684–686Google Scholar
- 26.Coven SL, Hollingsworth E, Stanek J, Walker D, Finlay JL (2016) EPI-03: establishing a baseline time-frame for symptom onset to definitive diagnosis of children with newly-diagnosed CNS tumors in Central Ohio. Neuro Oncol 63:S70–S71Google Scholar
- 32.Vuotto S, Krull K, Li C, et al (2019) Neurologic morbidities, emotional distress, and functional independence in adult survivors of childhood cancer treated with CNS-directed therapies: a report from the childhood cancer survivor studyGoogle Scholar